PPARG rs3856806 C&T Polymorphism Increased the Risk of Colorectal Cancer: A Case-Control Study in Eastern Chinese Han Population

摘要

Purpose: Functional variants in the peroxisome proliferator-activated receptor gamma ( PPARG ) and PPARG co-activator 1 ( PPARGC1 ) family (e.g., PPARGC1A and PPARGC1B ) genes were predicted to confer susceptibility to colorectal cancer (CRC). The aim of the present study was to explore the relationship between PPARG, PPARGC1A, PPARGC1B polymorphism and the risk of CRC. Patients and methods: We conducted a case-control study with 1,003 CRC cases and 1,303 controls. We selected the PPARG rs3856806 C&T, PPARGC1A rs2970847 C&T, rs8192678 C&T, rs3736265 G&A and PPARGC1B rs7732671 G&C and rs17572019 G&A SNPs to assess the relationship between PPARG, PPARGC1A, PPARGC1B their variants and risk of CRC. Results: We found that the PPARG rs3856806 C&T polymorphism increased the risk of CRC (TT vs. CC: adjusted OR, 1.59, 95% CI 1.08–2.35, P = 0.020; TT/CT vs. CC: adjusted OR, 1.26; 95% CI 1.06–1.49; P = 0.009 and TT vs. CC/CT: adjusted OR, 1.54; 95% CI 1.05–2.26; P = 0.028), even after a Bonferroni correction test. The stratified analysis revealed that the PPARG rs3856806 C&T polymorphism also increased the risk of CRC, especially in male, ≥61 years old, never smoking, never drinking, BMI ≥ 24 kg/m ~(2), colon cancer and rectum cancer subgroups. Conclusion: Our findings highlight that the PPARG rs3856806 C&T polymorphism may increase the risk of CRC. In the future larger sample size case-control studies with a detailed functional assessment are needed to further determine the relationship of the PPARG rs3856806 C&T polymorphism with CRC risk.